Reactivation of ERK Signaling causes resistance to EGFR kinase inhibitors

The clinical efficacy of EGFR kinase inhibitors is limited by the development of drug resistance. The irreversible EGFR kinase inhibitor WZ4002 is effective against the most common mechanism of drug resistance mediated by the EGFR T790M mutation. Here we show, in multiple complementary models, that...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Ercan, Dalia, Xu, Chunxiao, Yanagita, Masahiko, Monast, Calixte S., Pratilas, Christine A., Montero, Joan, Butaney, Mohit, Shimamura, Takeshi, Sholl, Lynette, Ivanova, Elena V., Tadi, Madhavi, Rogers, Andrew, Repellin, Claire, Capelletti, Marzia, Maertens, Ophélia, Goetz, Eva M., Letai, Anthony, Garraway, Levi A., Lazzara, Matthew J., Rosen, Neal, Gray, Nathanael S., Wong, Kwok-Kin, Jänne, Pasi A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2012
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3477553/
https://ncbi.nlm.nih.gov/pubmed/22961667
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-12-0103
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak